Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis.

J Immunol

Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY 10065; and

Published: September 2018

Psoriasis vulgaris is a common, heterogeneous, chronic inflammatory skin disease characterized by thickened, red, scaly plaques and systemic inflammation. Psoriasis is also associated with multiple comorbid conditions, such as joint destruction, cardiovascular disease, stroke, hypertension, metabolic syndrome, and chronic kidney disease. The discovery of IL-17-producing T cells in a mouse model of autoimmunity transformed our understanding of inflammation driven by T lymphocytes and associations with human inflammatory diseases, such as psoriasis. Under the regulation of IL-23, T cells that produce high levels of IL-17 create a self-amplifying, feed-forward inflammatory response in keratinocytes that drives the development of thickened skin lesions infiltrated with a mixture of inflammatory cell populations. Recently, the Food and Drug Administration approved multiple highly effective psoriasis therapies that disrupt IL-17 (secukinumab, ixekizumab, and brodalumab) and IL-23 (guselkumab and tildrakizumab) signaling in the skin, thus leading to a major paradigm shift in the way that psoriatic disease is managed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129988PMC
http://dx.doi.org/10.4049/jimmunol.1800013DOI Listing

Publication Analysis

Top Keywords

psoriasis
5
discovery il-23/il-17
4
il-23/il-17 signaling
4
signaling pathway
4
pathway treatment
4
treatment psoriasis
4
psoriasis psoriasis
4
psoriasis vulgaris
4
vulgaris common
4
common heterogeneous
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!